ArticleBiomedical engineering online2026
Synergistic effects of dexamethasone and vitamins D and K on mesenchymal stem cell differentiation.
Article in Biomedical engineering online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe ability to guide stem cells toward the bone-forming lineage is a fundamental aspect of regenerative medicine. Conventional protocols for osteogenic differentiation of mesenchymal stem cells typically rely on continuous exposure to the synthetic steroid dexamethasone, in combination with other supplements such as ascorbate and glycerophosphate. Although dexamethasone effectively induces bone-related gene expression and matrix mineralization, prolonged or excessive exposure can lead to adverse catabolic and cytotoxic effects. Therefore, there is a need to develop improved culture conditions that retain efficacy while enhancing physiological relevance, safety, and reproducibility. This study investigated whether 1-week dexamethasone exposure and supplementing the medium with vitamin D3 and the synthetic vitamin K analogue K3 could enhance osteogenic differentiation of bone marrow-derived mesenchymal stem cells.
methodsStem cells were cultured for 28 days in four types of osteogenic media differing in the duration of dexamethasone exposure and the presence of vitamins D3 and K3. Osteogenic differentiation was evaluated using histochemical staining for mineralized matrix, quantification of calcium deposition, analysis of alkaline phosphatase activity, fluorescence microscopy of cellular morphology and mitochondrial organization, and gene expression of osteogenic markers including RUNX2, alkaline phosphatase, osteocalcin, and bone morphogenetic protein 2.
resultsA short exposure to dexamethasone alone was insufficient to support robust osteogenic progression, confirming the importance of sustained stimulation. In contrast, the combination of vitamins D3 and K3 produced a clear synergistic effect, characterized by stronger mineralization, increased alkaline phosphatase activity, and enhanced expression of key osteogenic genes.
conclusionsThis study demonstrates that the combined use of vitamins D3 and K3, together with optimized dexamethasone exposure, provides a simple and biologically compatible strategy to improve the osteogenic differentiation of mesenchymal stem cells. This approach offers a physiologically relevant, safe, and cost-effective modification of standard osteogenic protocols and may contribute to the development of more efficient cell-based systems for bone tissue engineering and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.